



Giovanni Paganelli, MD

- In 1980 he graduated Doctor of Medicine and Surgery at the University of Bologna, afterward he specialized in Geriatrics and then in Nuclear Medicine
- From 1987 to 1988, he worked with the Oncology Group at the Hammersmith Hospital, Royal Postgraduate Medical School of London, perfecting a new technique (based on the avidin-biotin system) for tumor imaging and therapy using monoclonal antibodies.
- From 1989 to 1994 he worked in research and clinical activities within the Nuclear Medicine Dept. at the “Istituto Scientifico H San Raffaele” (Milan, Italy).
- From April 1994 to October 2013 has been appointed Director of the Nuclear Medicine Division at the European Institute of Oncology (Milan, Italy).
- From November 2013 at present he is Director of Nuclear Medicine and Radiometabolic Unit at Istituto Scientifico Romagnolo, IRST-IRCCS, Meldola, Italy
- In 1998 he has been awarded with the “Marie Curie Award” from the European Association of Nuclear Medicine for his work on Sentinel Node Biopsy in breast cancer.
- From February 2001 to December 2003: he has been an Expert of the “Consiglio Superiore di Sanità” (Italian Health Commission).
- He is member of the Editorial Board of several Scientific Journals

Research Activity:

- He has pioneered the use of ^{90}Y -Biotin in the antibody guided radiotherapy of gliomas
- In 1997 he has optimized the lymphoscintigraphic technique for the detection of the Sentinel Node in breast cancer and conceived a new non palpable lesions localization system named ROLL .
- The results of his researches (over 290 articles) have been published on the major international scientific journals.
- He owns the patent rights for 12 scientific patents.
- He has been invited by several Italian and international Universities to hold seminars and lecturers.
- His main field of interest is the “in-vivo” application of the avidin-biotin system (IART® system) in breast cancer and gliomas.
- At present, he is investigating new radiopharmaceuticals for targeted molecular radionuclide therapy in oncology (PRRT and IART® systems) and radiolabelled peptides in neuroendocrine tumors.